Value
9.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst target | 9.0 |
- ▸Attractively valued
SPTX · Why this verdict
Why Seaport Therapeutics (SPTX) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.7/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Seaport Therapeutics is backed by heavy insider buying and a favorable engine-calculated risk/reward setup, but weak fundamental quality, a large recent earnings miss, and falling volume distribution introduce meaningful near-term risk.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The company's most recent reported quarter missed estimates by a wide margin, with actual EPS of -$10.34 against an estimate of -$3.88, a -166.27% surprise. Earnings | Subsequent quarterly results should narrow the miss magnitude toward single-digit percentage surprises if forecasting improves. | →Stable |
| CounterLarge negative surprises in clinical-stage biotechs often reflect one-time R&D or trial-related charges rather than a deteriorating operating trend. | ||
Insiders have made significant net purchases over the trailing 90 days, totaling $20,035,768, or 1.82% of market cap, across 2 buy transactions with zero sells, a strongly bullish signal. Insider | The stock should see continued insider accumulation or at minimum no reversal to net selling over the next 2 quarters if this conviction is well-founded. | →Stable |
| CounterA large single insider purchase from a founder or major holder can reflect idiosyncratic capital allocation rather than a broad signal about undervaluation. | ||
The engine calculates a 2.98x asymmetry ratio with 44.6% upside potential against a 7% downside stop. Reward-to-risk math | Price should progress toward the $29.75 take-profit target over the next 12 months if the setup resolves favorably. | →Stable |
| CounterClinical-stage biotech names can gap sharply against a stop-loss level on binary trial or regulatory news, making the stated downside estimate unreliable. | ||
The company shows no competitive moat and a weak Piotroski F-Score of 2/9, reflecting below-average fundamental quality. Quality breakdown | The Piotroski F-Score should improve within 12 months if fundamentals strengthen. | →Stable |
| CounterA weak Piotroski score is typical and largely uninformative for a clinical-stage biotech with minimal revenue. | ||
On-balance volume is falling, indicating volume distribution, or selling pressure, even as the stock maintains a positive momentum gate. Momentum breakdown | On-balance volume should turn upward, signaling renewed accumulation, over the next quarter if the technical picture is to improve. | ↓Deteriorating |
| CounterFalling on-balance volume in a low-float, newly public biotech can be noisy and less predictive than in more heavily traded names. | ||
The company's most recent reported quarter missed estimates by a wide margin, with actual EPS of -$10.34 against an estimate of -$3.88, a -166.27% surprise.
→StableEarnings
- Expectation
- Subsequent quarterly results should narrow the miss magnitude toward single-digit percentage surprises if forecasting improves.
CounterLarge negative surprises in clinical-stage biotechs often reflect one-time R&D or trial-related charges rather than a deteriorating operating trend.
Insiders have made significant net purchases over the trailing 90 days, totaling $20,035,768, or 1.82% of market cap, across 2 buy transactions with zero sells, a strongly bullish signal.
→StableInsider
- Expectation
- The stock should see continued insider accumulation or at minimum no reversal to net selling over the next 2 quarters if this conviction is well-founded.
CounterA large single insider purchase from a founder or major holder can reflect idiosyncratic capital allocation rather than a broad signal about undervaluation.
The engine calculates a 2.98x asymmetry ratio with 44.6% upside potential against a 7% downside stop.
→StableReward-to-risk math
- Expectation
- Price should progress toward the $29.75 take-profit target over the next 12 months if the setup resolves favorably.
CounterClinical-stage biotech names can gap sharply against a stop-loss level on binary trial or regulatory news, making the stated downside estimate unreliable.
The company shows no competitive moat and a weak Piotroski F-Score of 2/9, reflecting below-average fundamental quality.
→StableQuality breakdown
- Expectation
- The Piotroski F-Score should improve within 12 months if fundamentals strengthen.
CounterA weak Piotroski score is typical and largely uninformative for a clinical-stage biotech with minimal revenue.
On-balance volume is falling, indicating volume distribution, or selling pressure, even as the stock maintains a positive momentum gate.
↓DeterioratingMomentum breakdown
- Expectation
- On-balance volume should turn upward, signaling renewed accumulation, over the next quarter if the technical picture is to improve.
CounterFalling on-balance volume in a low-float, newly public biotech can be noisy and less predictive than in more heavily traded names.
Per-dimension breakdown
Quality
2.5/10data confidence 86%| Component | Sub-score |
|---|---|
| Gross margin | 0.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| Moat | 5.5 |
| Piotroski F | 4.4 |
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
5.1/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.5 |
| MACD | 3.7 |
| OBV | 10.0 |
| MA position | 7.5 |
| Volume | 0.0 |
- ▸Volume accumulation (rising OBV)
Sentiment
8.0/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 7.3 |
| Price target | 9.9 |
| erm sentiment | 6.8 |
- ▸Light analyst coverage (5.0) — signal dampened
- ▸Analyst upside: 76%
Insider
8.5/10data confidence 100%| Component | Sub-score |
|---|---|
| materiality | 9.0 |
| insider conviction | 8.0 |
| holder change | 10.0 |
| notable moves | 7.0 |
- ▸Heavy insider buying — $20,035,768 (1.782% of mkt cap)
- ▸Institutions accumulating
Peer rank
5.4/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 5.0 |
| growth rank | 5.0 |
Technical
4.7/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 2.6 |
| support resistance | 2.7 |
| 52w position | 8.8 |
Risk (lower is worse)
4.3/10data confidence 80%| Component | Sub-score |
|---|---|
| short interest | 7.3 |
| days to cover | 0.0 |
| volatility | 0.0 |
| debt equity | 9.9 |
Catalyst
2.2/10data confidence 75%| Component | Sub-score |
|---|---|
| erm | 6.5 |
| earnings history | 0.0 |
| surprise avg | 0.0 |
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCK:QUALITY_FLOORPassed (8)
- MOMENTUM:5.1>=4.5
- ASYMMETRY:3.5>=1.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:NO_DATE
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (0)
none
Warning (1)
- MOMENTUM:5.1<5.5 (soft — BUY_NOW allowed but watch)
Reward-to-Risk
3.53
Upside
+53.0%
Downside
15.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeInst Constrain — Small cap ($1.1B) below institutional reach
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The SELL_IF_HOLDING verdict reflects clean gate clearance against Value at 9.0 and asymmetric R:R of 3.53.
The strongest dimensions are Value at 9.0, Insider at 8.5, and Sentiment at 8.0; the weakest are Catalyst at 2.2, Quality at 2.5, and Risk (lower is worse) at 4.3. The V9 engine cleared all gates with 1 warning, producing an asymmetric reward-to-risk of 3.53 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Heavy Insider Buying
Trip ifInsider sell value exceeds $5,000,000 over a rolling 90-day window, reversing the current bullish signal.
- P2Favorable Risk Reward Asymmetry
Trip ifPrice falls below the $19.13 stop-loss, invalidating the 2.98x asymmetry setup.
- P3Weak Fundamental Quality
Trip ifPiotroski F-Score rises above 4 out of 9.
- P4Large Earnings Miss
Trip ifThe company's EPS surprise exceeds -20% at its next earnings release.
- P5Falling Volume Distribution
Trip ifOn-balance volume trend rises for more than 2 consecutive months.